

for GI genogroup noroviruses. *Nat Microbiol.* 2025. <https://doi.org/10.1038/s41564-025-01952-6>.

*Inventors:* Mario Roederer, Inga Rimkute, Peter Kwong, Adam Olia, Raffaello Verardi (all of NIAID VRC).

*Intellectual Property:* HHS Reference No. E-025-2024; Provisional Patent Application 63/653,691, filed on May 30, 2024.

*Licensing Contact:* To license this technology, please contact Brian Bailey at 240-669-5128 or [brian.bailey@nih.gov](mailto:brian.bailey@nih.gov) at [brian.bailey@nih.gov](mailto:brian.bailey@nih.gov), and reference E-025-2024.

*Collaborative Research Opportunity:* The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128 or [brian.bailey@nih.gov](mailto:brian.bailey@nih.gov), and reference E-025-2024.

Dated: June 9, 2025.

**Surekha Vathyam,**

*Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2025-10921 Filed 6-13-25; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Terrence Joyce at 240-987-2347, or [terrence.joyce@nih.gov](mailto:terrence.joyce@nih.gov). Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

#### SUPPLEMENTARY INFORMATION: Technology description follows:

##### Francisella Lipids as Broad Anti-Inflammatory Therapeutics

###### Description of Technology

Anti-inflammatory treatments, particularly those used in the context of viral infection, have been shown to greatly inhibit the overall immune response, which can result in poor immunity and failure to control or clear the infection. Novel alternatives that can effectively attenuate inflammation without the more serious side effects of steroid medications (*e.g.*, global immune suppression, muscle weakness, etc.) may have substantial use across a wide range of disease areas.

*Francisella tularensis* (FT), the causative agent of tularemia, exhibits a potent ability to induce rapid suppression of inflammatory responses in host cells. Building on prior work that demonstrated the ability of crude and enriched lipids from virulent FT strains to dampen inflammation triggered by a variety of sources, researchers at the National Institute of Allergy and Infectious Disease (NIAID) have developed FT lipid preparations with strong potential for the prophylactic/therapeutic treatment of viral-mediated inflammation—without deleterious effects on the development of anti-viral immunity.

The NIAID data further show that these FT lipid preparations are relatively non-toxic to cells, do not adversely affect the functioning of T cells, and act in part by inhibiting production of inflammatory mediators, highlighting other potential therapeutic targets such as allergic and autoimmune-associated inflammation.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

###### Potential Commercial Applications:

- Well-tolerated, short-term prophylactic or therapeutic treatment of inflammation across multiple disease areas (viral infection, autoimmunity, etc.)

###### Competitive Advantages:

- Potential alternative that can overcome compromises to immunity and other side effects associated with traditional anti-inflammatory treatment

###### Development Stage: Preclinical.

###### Relevant Publications:

- Crane DD, et al. Lipids derived from virulent *Francisella tularensis* broadly inhibit pulmonary inflammation via toll-like receptor 2

and peroxisome proliferator-activated receptor  $\alpha$ . *Clin Vaccine Immunol.* 2013;20(10):1531-1540.

- Ireland R, et al. *Francisella tularensis* SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. *J Immunol.* 2013;191(3):1276-1286.

*Inventors:* Catherine Bosio, Glenn Nardone, Robin Ireland (all of NIAID)

*Intellectual Property:* HHS Reference No. E-142-2016; Provisional Patent Application 62/319,692, filed on April 7, 2016; 16,091,768, filed on October 5, 2018, issued December 20, 2022; PCT Application No. PCT/US2017/026467, filed on April 6, 2017; European Patent App. No 17721893.0, filed on April 6, 2017.

*Licensing Contact:* To license this technology, please contact Terrence Joyce at 240-987-2347 or [terrence.joyce@nih.gov](mailto:terrence.joyce@nih.gov), and reference E-142-2016.

*Collaborative Research Opportunity:* The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Terrence Joyce at 240-987-2347 or [terrence.joyce@nih.gov](mailto:terrence.joyce@nih.gov), and reference E-142-2016.

Dated: June 9, 2025.

**Surekha Vathyam,**

*Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2025-10919 Filed 6-13-25; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Wade Green at 301-761-7505, or

wade.green@nih.gov. Information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

#### **SUPPLEMENTARY INFORMATION:**

Technology description follows:

#### **Broadly Neutralizing Influenza Hemagglutinin Stem-Directed Antibodies**

##### *Description of Technology*

In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance and are useful for only a limited post-infection period.

The highly conserved epitopes in the stem region of the influenza hemagglutinin (HA) protein are ideal targets for new vaccines, as they elicit broadly neutralizing antibodies. In light of this, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) cloned and expressed HA stem-specific monoclonal antibodies (mAbs) from B cells isolated from human participants in influenza vaccine clinical trials. Four mAbs exhibited particularly potent neutralizing profiles against H1N1 strains, three exhibited very strong neutralization profiles against H3N2 strains, and two exhibited a good neutralization profile across all subtypes tested. These mAbs may help to substantially reduce global influenza disease burden given their potential to become effective therapeutic and prophylactic agents against a broad range of H1N1 and H3N2 influenza strains.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

##### *Potential Commercial Applications:*

- Prophylactic or therapeutic strategies against influenza infection

##### *Competitive Advantages:*

- Greater neutralization potency against H1N1 and H3N2 strains than observed for other high-profile candidates tested in phase II clinical trials

*Developmental Stage:* Preclinical.

##### *Publications:*

- Andrews SF, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. *Sci. Transl. Med.* 2023;15:eade4976.
- Mantus GE, et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem-specific human B cells. *Sci. Transl. Med.* 2025;17:eadr8373.

*Inventors:* Sarah Andrews (NIAID), Grace Mantus (NIAID), Ankita Chopde (NIAID), Adrian Creanga (NIAID), Rebecca Gillespie (NIAID); Masaru Kanekiyo (NIAID); Lauren Cominsky (former NIAID; UPenn); Julie Raab (former NIAID; UColorado)

*Intellectual Property:* HHS Reference No. E-026-2024; Provisional Patent Application No.: 63/605,374, filed on December 1, 2023, and PCT Patent Application No. PCT/US2024/057131, filed on November 22, 2024.

*Licensing Contact:* To license this technology, please contact Wade Green at 301-761-7505, or wade.green@nih.gov, and reference E-026-2024.

*Collaborative Research Opportunity:* The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Wade Green at 301-761-7505, or wade.green@nih.gov, and reference E-026-2024.

Dated: June 9, 2025.

**Surekha Vathyam,**

*Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2025-10918 Filed 6-13-25; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HOMELAND SECURITY**

**[Docket No. DHS-2025-0024]**

### **Homeland Security Advisory Council; Notice of Meeting**

**AGENCY:** Office of Partnership and Engagement, Department of Homeland Security.

**ACTION:** Notice of Open Federal Advisory Committee meeting.

**SUMMARY:** The Office of Partnership and Engagement is publishing this notice to announce that the Homeland Security Advisory Council will meet in person on Monday, June 30, 2025. This meeting

will be open to the public via livestream. This meeting will be led by senior leadership of Homeland Security. Senior Leadership will introduce the new Chair and Vice Chair of the Council, and the Council will discuss the Council's purpose, focus, and potential taskings.

#### **DATES: Meeting Registration:**

Registration to attend the meeting is required and must be received via email no later than 5 p.m. Eastern Daylight Time on Friday, June 27, 2025. The meeting will take place from 1 p.m. to 4 p.m. Eastern Daylight Time on Monday, June 30, 2025. The meeting will be open to the public via livestream. The meeting may end early if the Council has completed its business.

**ADDRESSES:** The Council meeting will be held at the Department of Homeland Security—St. Elizabeths Campus in Washington, DC. Members of the public may attend via livestream following the process outlined below. For those attending the meeting you will be in listen-only mode.

**FOR FURTHER INFORMATION CONTACT:** Alexander Jacobs, Alternate Designated Federal Officer, Homeland Security Advisory Council at (202)269-2419 or HSAC@hq.dhs.gov.

**SUPPLEMENTARY INFORMATION:** The Council provides organizationally independent, strategic, timely, specific, actionable advice, and recommendations to the Secretary of Homeland Security on matters related to homeland security. The Council serves strictly as an advisory body with the purpose of providing advice upon request of the Secretary. The Council members shall all be national leaders drawn from the following fields: police, fire, emergency medical services and public works; public health; non-profit organizations; state, local, and tribal officials; national policy makers; experts in academia and the research community; and leaders from the private sector.

Notice of this meeting is given under Section 10(a) of the Federal Advisory Committee Act, Public Law 92-463 (5 U.S.C. Ch. 10), which requires each council meeting to be open to the public unless the President, or the head of the agency to which the advisory council reports, determines that a portion of the meeting may be closed to the public in accordance with 5 U.S.C. 552b(c).

**Agenda:** The Council will meet in an open session from 1 p.m. until 4 p.m. Eastern Daylight Time. The meeting will include: (1) the swearing in of members; (2) remarks from the Senior Leadership; (3) introduction of and opening remarks